Matthew Pauls
CIK 1573429 · CHIEF EXECUTIVE OFFICER · last filed 2026-10-06
Matthew Pauls is a CHIEF EXECUTIVE OFFICER who has filed 50 SEC Form 4 insider transactions across 7 companies since 2013. The most recent filing shows the insider sold $16.5K of PTHS on Oct 6, 2026. Across all open-market trades the lifetime net is −$814.8K, making them a net seller over the disclosed history. Current disclosed insider exposure totals $5.8M across reported positions. 2 SEC filings were submitted jointly with PALVELLA THERAPEUTICS, INC.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
SVRA price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
SUITE C
MONMOUTH JUNCTION, NJ 08852
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| PTHS | Director | 13,578 | $9.52 | $129.3K | -$53.5K | 6 | 2026-10-06 |
| PVLA | Director | — | $173.44 | — | $0 | 1 | 2026-07-01 |
| SOLENO THERAPEUTICS INC (SLNO) Delisted | Director | 0 | $53.01 | $0 | -$424.8K | 5 | 2026-05-18 |
| SVRA | CHIEF EXECUTIVE OFFICER | 1,188,050 | $4.82 | $5.72M | -$336.5K | 21 | 2025-12-16 |
| Strongbridge Biopharma plc (SBBP) Delisted | President & CEO | 72,608 | $2.00 | $145.2K | $0 | 3 | 2019-02-22 |
| MSTX | Director | — | $11.80 | — | $0 | 3 | 2017-01-23 |
| INSM | Chief Commercial Officer | — | $112.08 | — | $0 | 3 | 2014-01-14 |
Recent Filings
50 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-10-06 | PTHS | Sell (S) | −786 | -$16.5K | EDGAR |
| 2026-07-07 | PTHS | Sell (S) | −786 | -$20.6K | EDGAR |
| 2026-07-01 | PVLA | Grant (A) | — | $0 | EDGAR |
| 2026-05-18 | SOLENO THERAPEUTICS INC (SLNO) Delisted | Disp (D) | −10,491 | $0 | EDGAR |
| 2026-04-06 | PTHS | Sell (S) | −786 | -$16.4K | EDGAR |
| 2026-04-01 | PTHS | Grant (A) | +25,478 | $0 | EDGAR |
| 2025-12-16 | SVRA | Mixed | −324,700 | -$1.35M | EDGAR |
| 2025-12-12 | PTHS | Mixed | +1,074 | $0 | EDGAR |
| 2025-12-11 | SVRA | Gift (G) | −23,629 | $0 | EDGAR |
| 2025-07-07 | PTHS | Grant (A) | — | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.